Safety Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

  • STATUS
    Not Recruiting
  • participants needed
    20
  • sponsor
    Cantex Pharmaceuticals
Updated on 19 September 2021
karnofsky performance status
MRI
glioblastoma multiforme
temozolomide
disulfiram

Summary

This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM. Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months. Patients will be evaluated for response every 8 weeks. Patients will be followed up 2 years after the last dose of DSF-Cu.

Details
Condition Recurrent Glioblastoma
Treatment Disulfiram/Copper
Clinical Study IdentifierNCT03034135
SponsorCantex Pharmaceuticals
Last Modified on19 September 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note